Opinion|Videos|March 4, 2024
Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Author(s)Rana R. McKay, MD, Neal Shore, MD, FACS
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
China's NMPA Approves Pirtobrutinib Across CLL
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5